The conjecture in #msg-58508360 remains operative. If NVS/MNTA’s patent-infringement suit is not dismissed, legal discovery pursuant to the fact-finding of the case could prove embarrassing to Teva by showing that Teva never had a credible Lovenox program, but rather had been misleading the investment community for several years.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”